40PInterest and potential of genetically engineered cord blood derived T cells for cancer immunotherapy. (17th December 2018) - Marton, C; Mercier-Letondal, P; Deschamps, M; Ferrand, C; Adotevi, O; Borg, C; Galaine, J; Godet, Y